PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-40.99%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-58.48%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-125.13%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-125.13%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-106.93%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-107.07%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-107.25%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
-0.20%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-30.64%
Negative OCF growth while CVE is at 2.02%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-83.52%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
13.34%
10Y revenue/share CAGR under 50% of CVE's 46.40%. Michael Burry would suspect a lasting competitive disadvantage.
-42.43%
Negative 5Y CAGR while CVE stands at 46.40%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-74.95%
Negative 3Y CAGR while CVE stands at 46.40%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
146.90%
Positive long-term OCF/share growth while CVE is negative. John Neff would see a structural advantage in sustained cash generation.
-63.85%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-56.63%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-158.75%
Negative 10Y net income/share CAGR while CVE is at 174.77%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-102.39%
Negative 5Y net income/share CAGR while CVE is 174.77%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-103.94%
Negative 3Y CAGR while CVE is 174.77%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
375.33%
10Y equity/share CAGR above 1.5x CVE's 4.10%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
45.90%
5Y equity/share CAGR above 1.5x CVE's 4.10%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
-15.25%
Negative 3Y equity/share growth while CVE is at 4.10%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
956.80%
Stable or rising dividend while CVE is cutting. John Neff sees a strong advantage in consistent shareholder returns vs. a struggling peer.
208.71%
Stable or rising mid-term dividends while CVE is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
-0.47%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
8.11%
AR growth well above CVE's 1.99%. Michael Burry fears inflated revenue or higher default risk in the near future.
-50.00%
Inventory is declining while CVE stands at 2.09%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
0.71%
Positive asset growth while CVE is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-0.13%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
0.57%
Debt shrinking faster vs. CVE's 56.91%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
36.11%
SG&A growth well above CVE's 66.41%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.